Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Benefit and formulary strategy
Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment
The EXAMINE and SAVOR-TIMI 53 studies were excluded from sensitivity analyses because DPP-IV inhibitor drugs did not show CV benefit in their individual trials
CL post account favorites hidden CL
doi: 10.1016/j.immuni.2023.06.021
This makes it ideal for use in medical settings where contamination could be an issue
/assets/images/provider/photos/2805921.jpeg)
US$ 22.27
US$ 24.97
US$ 28.09
/assets/images/provider/photos/2733167.jpeg)
US$ 28.27
